Takeda Achieves Key Regulatory Milestone as FDA Accepts NDA and Grants Priority Review for Oveporexton
U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda’s Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type 1 Takeda today announced that the U.S. Food and Drug Administration (FDA) accepted its New…
Muse Brings Deep Sleep Stimulation to the Home
Muse Brings Deep Sleep Stimulation Home Muse today announced Deep Sleep Boost (DSB), a new sleep feature designed to help users sustain deeper, more stable slow-wave sleep. Powered by Muse S Athena, Deep Sleep Boost delivers targeted slow-wave sleep support…
Galux Raises $29M in Series B Funding to Advance AI-Driven Protein Design for Drug Discovery
Galux Raises $29M Series B to Advance AI-Driven Protein Design for Drug Discovery Galux, a South Korea-based biotech pioneering AI-driven protein therapeutics design, today announced the successful completion of a $29 million (KRW 42 billion) Series B financing. With this…
athenahealth and b.well Introduce Patient-Controlled Digital Health Data Sharing at the Point of Care
athenahealth and b.well Introduce Patient-Controlled Digital Health Data Sharing at the Point of Care athenahealth and b.well Connected Health today announced a new point-of-care workflow allowing patients to securely share their health information digitally during intake—without paper forms, faxes, or multiple portal logins.…
Kradle Expands Feline Supplement Portfolio with Kradle Max Full-Spectrum Hemp Calming Tincture for Cats
Kradle Expands Feline Supplement Portfolio With Kradle Max Full-Spectrum Hemp Calming Tincture for Cats Kradle, a premium pet wellness brand known for its innovative and easy-to-use natural calming solutions for dogs and cats, today announced the launch of Kradle Max…
Keepit Receives 2025 Backup and Disaster Recovery Award from Cloud Computing Magazine
Keepit Receives 2025 Backup and Disaster Recovery Award from Cloud Computing Magazine Keepit, the only independent, cloud-native data protection and recovery provider, today announced that TMC, a global, integrated media company, has named Keepit platform as a 2025 Cloud Computing Backup…
Global Mobile Medical Association Launches Unified Network to Transform Community Healthcare
The Global Mobile Medical Association Launches to Transform Community Healthcare with Unified Network The Global Mobile Medical Association (GMMA), the world’s first comprehensive network dedicated to advancing the mobile healthcare model, officially launched today. GMMA represents a turning point for…
Zoya Technologies Unveils ZoyeMed 3.0, an Edge-Native Autonomous AI Clinic, at WHX Dubai
Zoya Technologies Unveils ZoyeMed 3.0, an Edge-Native Autonomous AI Clinic, at WHX Dubai Zoya Technologies today unveiled ZoyeMed 3.0, an edge-native clinical terminal designed to deliver autonomous primary and acute care with humans in the loop. Presented at WHX Dubai 2026, the…
Nuvation Bio Launches Global Phase 3 SIGMA Trial of Safusidenib for IDH1-Mutant Glioma
Nuvation Bio Announces Pivotal Global Phase 3 SIGMA Trial (G203) for Safusidenib in IDH1-Mutant Glioma Nuvation Bio Inc. a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced finalization of a protocol amendment to the…
GE HealthCare Unveils ReadyFix Solution to Boost Efficiency and Care Delivery
GE HealthCare launches ReadyFix fleet management solution to help enhance operational efficiency and reliable patient care GE HealthCare today announced the United States launch of ReadyFix™, a remote fleet management solution designed to help healthcare systems support device uptime. ReadyFix will seamlessly…
Estrella Immunopharma Showcases Updated EB103 Data at 2026 ASTCT® & CIBMTR® Tandem Meetings
Estrella Immunopharma Presents Promising Updated Data on EB103 in Oral Presentation at the 2026 Tandem Meetings of ASTCT® & CIBMTR® Estrella Immunopharma, Inc. (Nasdaq: ESLA, ESLAW) a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases,…
VectorY Therapeutics Doses First Participant in Phase 1/2 PIONEER-ALS Trial of VTx-002 for ALS
VectorY Therapeutics Announces First Participant Dosed in Phase 1/2 PIONEER-ALS Clinical Trial of VTx-002 in People with Amyotrophic Lateral Sclerosis (ALS) VectorY Therapeutics, a leader in vectorized antibody therapies for neurodegenerative diseases, announced today that the first participant has been…